---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021220"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:23:59.533932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials

## Summary
- Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.
- Net proceeds to fund DM199 phase 2/3 ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia.
- Cash runway extended into Q3 2026.
- Non-management related parties committed $6.0M (2.4M shares); exempt from MI 61-101 valuation and minority approval.

## SEC filing metadata
- accession: 0001437749-24-021220
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/0001437749-24-021220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/dmtp20240625_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021220
- JSON: https://secwatch.observer/filing/0001437749-24-021220.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.